) [153]. This process is now not scalable mainly because it depends on highly-priced startup substrates that may be applied to provide psilocybin in less expensive chemical synthesis methodologies. A methodology for de novo creation of psilocybin and tryptamine derivatives in Saccharomyces cerevisiae,Swift and sustained symptom reduction following